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AbstrACt
Introduction Masked uncontrolled hypertension (MUCH) 
carries an increased risk of cardiovascular (CV) complications 
and can be identified through combined use of office (O) 
and ambulatory (A) blood pressure (BP) monitoring (M) in 
treated patients. However, it is still debated whether the 
information carried by ABPM should be considered for MUCH 
management. Aim of the MASked-unconTrolled hypERtension 
management based on OBP or on ambulatory blood pressure 
measurement (MASTER) Study is to assess the impact on 
outcome of MUCH management based on OBPM or ABPM.
Methods and analysis MASTER is a 4-year prospective, 
randomised, open-label, blinded-endpoint investigation. A 
total of 1240 treated hypertensive patients from about 40 
secondary care clinical centres worldwide will be included 
-upon confirming presence of MUCH (repeated on treatment 
OBP <140/90 mm Hg, and at least one of the following: 
daytime ABP ≥135/85 mm Hg; night-time ABP ≥120/70 mm 
Hg; 24 hour ABP ≥130/80 mm Hg), and will be randomised 
to a management strategy based on OBPM (group 1) or on 
ABPM (group 2). Patients in group 1 will have OBP measured 
at 0, 3, 6, 12, 18, 24, 30, 36, 42 and 48 months and taken as a 
guide for treatment; ABPM will be performed at randomisation 
and at 12, 24, 36 and 48 months but will not be used to take 
treatment decisions. Patients randomised to group 2 will have 
ABPM performed at randomisation and all scheduled visits as 
a guide to antihypertensive treatment. The effects of MUCH 
management strategy based on ABPM or on OBPM on CV and 
renal intermediate outcomes (changing left ventricular mass 
and microalbuminuria, coprimary outcomes) at 1 year and on 
CV events at 4 years and on changes in BP-related variables 
will be assessed.
Ethics and dissemination MASTER study protocol has 
received approval by the ethical review board of Istituto 
Auxologico Italiano. The procedures set out in this protocol are 
in accordance with principles of Declaration of Helsinki and 
Good Clinical Practice guidelines. Results will be published in 
accordance with the CONSORT statement in a peer-reviewed 
scientific journal.
trial registration number NCT02804074; Pre-results.
strengths and limitations of this study
 ► The MASked-unconTrolled hypERtension manage-
ment based on office BP (OBP)  or on ambulatory 
blood pressure measurement Study is the first ran-
domised controlled study so far addressing an im-
portant and still controversial issue, that is, whether 
using ambulatory BP monitoring rather than OBP 
measurements as a guide to antihypertensive treat-
ment confers any benefit in terms of cardiovascular 
prevention.
 ► For practical reasons, a double-blind study design 
could not be implemented.
 ► Due to the multicentre nature of our study which 
includes hypertension centres from all over the 
world, there is the theoretical possibility of a dropout 
rate larger than expected. For this reason, howev-
er, we have implemented a strict study monitoring 
web-based.
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IntroduCtIon 
The finding in untreated hypertensives of normal blood 
pressure (BP) levels when measured in the medical office 
accompanied by elevated out-of-office BP as assessed by 
either 24 hour ambulatory BP monitoring (ABPM) or 
home BP monitoring (HBPM) is defined as ‘masked 
hypertension’. This condition is relatively common, 
characterising 10%–15% of individuals in a population.1 
Remarkably, even after initiation of antihypertensive 
treatment, a substantial number of patients continue to 
show elevated BP levels out of the office, despite having 
apparently well-controlled BP levels during the medical 
visit. This condition has been defined as ‘masked uncon-
trolled hypertension’ (MUCH), and in a population of 
hypertensive patients under treatment has been reported 
to occur in as much as 30%–31% of cases.2 Moreover, 
there is evidence that prescription of antihypertensive 
treatment without adequate care of 24-hour BP coverage 
and, without implementation of ABPM in the assessment 
of treatment effects, may indeed be responsible for an 
increase in the frequency of MUCH.3 As in the case 
of MH, MUCH has been associated with an increased 
cardiovascular (CV) risk which is very similar to that 
of sustained hypertension and sustained uncontrolled 
hypertension in treated patients (ie, persistent eleva-
tion in both office and out-of-office BP levels).3 4 Several 
hypertension guidelines have indeed included suspicion 
of these conditions among the key clinical indications 
for out-of-office BP monitoring.5–11 The superiority of 
out-of-office BP versus office BP (OBP) measurements 
has been recently emphasised also by hypertension 
management guidelines, in particular by the National 
Institute of Health and Care Excellence guidelines 
which have recommended use of a time-restricted ABPM 
before starting treatment in patients with elevated 
OBP.12 However, key evidence from randomised ad hoc 
intervention trials on the benefits of using out-of-office 
BP measurement for assessment of BP control during 
the follow-up of treated hypertensive patients is still 
lacking. With the aim to better explore this issue, the 
MASTER Study (MASked-unconTrolled hypERtension 
management based on office BP or on ambulatory blood 
pressure measurement) will evaluate whether an ABPM-
based hypertension management strategy is superior to 
an OBP monitoring (OBPM)-based strategy in changing 
left ventricular mass (LVM) and microalbuminuria 
(coprimary outcomes) at 1 year, in preventing CV events 
(secondary outcome) at 4 years and in improving several 
BP-related variables throughout the study. The MASTER 
study, focusing on MUCH patients, is thus expected to 
provide useful information aimed at finally clarifying 
whether a management strategy based on out-of-office 
BP measurements might provide a greater benefit in 
terms of prevention or regression of organ damage and 
CV events than a management strategy based on OBP 
readings only, thereby assessing the actual value of using 
out-of-office BP in improving CV protection. 
MEthods
study design
The present study is a 4-year prospective, randomised, 
open-label, blinded-endpoint (PROBE) study aimed 
at comparing a management strategy for patients with 
MUCH, based on OBPM as a guide to antihypertensive 
treatment (group 1) versus a management strategy based 
on use of ABPM for the same purpose (group 2). The 
study will have a period of 2 years for the enrolment of 
the requested number of patients; and an average 4-year 
follow-up period (3 to 5 years).
Study endpoints are changes in LVM and microalbu-
minuria (coprimary outcomes) at 1 year, prevention of 
CV events including all-cause mortality, CV morbidity and 
mortality (secondary outcomes) at 4 years and improve-
ment of several BP-related variables throughout the study 
(tertiary outcome). Following a parallel group study 
design, patients will be randomised to one of the two 
management strategies by a centralised computer-gener-
ated sequence with an allocation ratio of 1:1.
sample selection
Recruitment
MASTER is a multicentre, multinational study including 
around 40 clinical centres from different continents: 
Europe (Austria, Belgium, Croatia, Georgia, Germany, 
Italy, Poland, Romania, Russia, Serbia, Spain, Sweden), 
Asia (China, India, Korea) and South America (Argen-
tina, Brazil, Venezuela). A list with the participating 
centres is provided in the online supplementary file 1.
To all participating centres, the coordinating centre in 
Milan will supply the due study documentation, including 
a description of the protocol and of the expected tasks, 
and the files to be signed in relation to study participa-
tion agreement. In order to guarantee the necessary 
data quality, each participating centre will be asked to 
submit to the coordinating centre information on the 
available devices for collection of the data required by the 
protocol. They will also be asked to send a sample of the 
recorded files related to specific study variables for quality 
check and file approval by the coordinating centre team. 
This will be specifically required for digital ECG files, for 
cardiac ultrasound records, for 24 hour ABPM files and 
for HBP records. If the centre fulfils all requirements and 
complies with study quality standards, an official agree-
ment will be signed with the coordinating centre before 
trial can be started. Approval by local ethics committee 
will also be required for each participating centre.
screening and randomisation
Around 40 subjects will be enrolled in each centre 
upon verifying the study eligibility criteria listed in box 1.
Patients are to be enrolled for screening and randomis-
ation over 1 year (a maximum of 2 years will be allowed). 
During the screening period (1 month before randomisa-
tion), eligibility of the patient will be checked and baseline 
measurements performed. Initial assessment of selection 
criteria based on subjects’ clinical history will take place 
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and, in case the subject is potentially eligible, the partici-
pation in the study will be proposed and informed consent 
obtained. During one or more screening visits, according 
to the need of the enrolling unit, the additional evalu-
ations needed for a complete assessment of eligibility 
criteria will be performed, ie, full medical history, physical 
examination, blood and urine samples, conventional BP 
measurements, ABPM placement for 24 hour recording 
(device to be removed on the following day). Once 
the diagnosis of MUCH has been made, baseline study 
variables will be collected. These include 7 days HBPM 
through use of oscillometric devices validated by means 
of international protocols, ECG and echocardiographic 
examinations and blood and urine tests. Blood samples 
will be obtained for assessment of estimated glomerular 
filtration rate (eGFR), plasma creatinine, plasma glucose, 
glycated haemoglobin (HbA1c), uric acid, serum sodium 
and potassium and plasma lipids. Two blood samples will 
also be collected at follow-up visit 1 and at follow-up visit 
3 in order to create a study biobank for future analyses. 
Spot urine samples for urine albumin:creatinine ratio 
(UACR) will be taken twice, once in the morning before 
application of the ABPM device, and another time on the 
following morning when subjects will return to the clin-
ical center for removing the ABPM device.
At each study site, the responsible investigator will 
arrange a randomisation visit (within 1 month after the 
screening period) during which eligible patients (ie, 
those found to have MUCH) will be randomised to one 
of the two study groups following the dynamic allocation 
method for balancing baseline covariates (specifically 
centre, age, sex, presence of diabetes and baseline office 
systolic BP (SBP)) proposed by Xhiao et al in 2012.13 The 
patient’s randomisation number and allocation will be 
generated by a central computer using an online algo-
rithm inbuilt on the electronic-Clinical Report Form 
(e-CRF). This approach adapts the algorithm proposed 
by Frane et al to obtain marginal balance for both contin-
uous and categorical covariates, adding Efron’s biased 
coin method to decrease the predictability of treatment 
assigned to a new patient.14 This aspect is very important 
especially for unblinded trials. The original R code to 
perform this algorithm, furnished by the author, will be 
set on the platform managing the e-CRF.
blinding (masking)
Because the MASTER is an open-label study, blinding will 
apply only for the endpoints. Thus, both participants and 
investigators will not be blinded to the allocated inter-
vention. In order to guarantee the blind assessment of 
the coprimary end point of LVM, the personnel involved 
in its assessment (ie, sonographers) will be blinded to 
the patient’s allocated management strategy. In addi-
tion, ABPM data of patients enrolled to group 1 will be 
directly uploaded on the e-CRF and will not be available 
to the investigators in charge of treatment decisions. The 
role of the Event Adjudicating Committee (EAC) of the 
MASTER Study is essential in a trial such as MASTER, 
necessarily designed as a PROBE trial. EAC within the 
MASTER study will be responsible for verifying and adju-
dicating in a blinded fashion all events representing 
primary, secondary and tertiary outcomes of the study, as 
well as all serious adverse events occurring in the course 
of the trial. For this reason, the General Coordinating 
Centre in Milan will insure that all outcome documenta-
tions sent to EAC is blinded for management strategy and 
intensity of antihypertensive therapy. Documentation of 
each outcome occurring in patients will be sent (electron-
ically or by fax) to two experts and to a third one in case 
the first two do not reach an agreement. Only validated 
outcomes will enter the final data analysis.
box 1 Inclusion and exclusion criteria for enrolment and 
exclusion criteria for enrolment
Inclusion criteria
 ► Male and female subjects;
 ► Age 40–80 years;
 ► Diagnosis of masked uncontrolled (on treatment) hypertension: of-
fice blood pressure (BP) <140/90 mm Hg, and one or more of the 
following situations:
 – Ambulatory daytime BP ≥135/85 mm Hg
 – Ambulatory night-time BP ≥120/70 mm Hg
 – Ambulatory 24 hours BP ≥130/80 mm Hg
 ► Estimated glomerular filtration rate (eGFR)  ≥45 mL/min/1.73 m2 
(Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cre-
atinine equation 2009).
Exclusion criteria
 ► eGFR <45 mL/min/1.73 m2 (CKD-EPI creatinine equation 2009), and 
in particular severe chronic renal failure defined as serum creati-
nine >250 µmol/L;
 ► One of the following conditions:
 – Persistent atrial fibrillation
 – Evidence of severe cardiac valve disease (ie, >2/4 grade at echo-
cardiographic examination)
 – Moderate and severe aortic stenosis
 – Presence of cardiomyopathy
 – Symptomatic heart failure or ejection fraction at or below 45%
 ► Patients in unstable clinical conditions;
 ► Known secondary hypertension;
 ► Orthostatic hypotension (systolic blood pressure fall >20 mm Hg on 
standing);
 ► Dementia (clinical diagnosis);
 ► Hepatic disease as determined by either aspartate transaminase or 
alanine transaminase values >2 times the upper reference limit;
 ► History of gastrointestinal surgery or disorders which could interfere 
with drug absorption;
 ► Known allergy or contraindications to one of the drugs to be admin-
istered in the study;
 ► History of malignancy including leukaemia and lymphoma (but not 
basal cell skin cancer) within the last 5 years;
 ► History of clinically significant autoimmune disorders such as sys-
temic lupus erythematosus;
 ► History of drug or alcohol abuse within the last 5 years;
 ► History of non-compliance to medical regimens and/or patients who 
are considered potentially unreliable;
 ► Inability or unwillingness to give free informed consent;
 ► Pregnancy or planned pregnancy during study period.
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Interventions
Blood pressure levels in both study groups will be measured 
by three BP measurement techniques (OBP, HPB and 
24 hour ABPM) following the recommendations issued by 
the European Society of Hypertension/European Society 
of Cardiology hypertension guidelines5 and BP moni-
toring groups.6–8 Indications on how to measure BP in the 
office, at home and in ambulatory conditions over 24 hours 
are provided in the supplemental operation manual. In order 
to standardise ABPM and OBPM data collection and analysis 
as much as possible, 24 hours ABPM in MASTER Study will 
be preferentially performed with A&D TM2430 device and 
OBP levels will be measured with A&D UA-651BLE device 
provided by the coordinating centre, thanks to a non-con-
ditioning support given by the A&D Company (A&D Engi-
neering, San Jose, California, USA). For HBPM, any of 
the currently available validated devices can be employed. 
Patients randomised to be managed based on OBP (group 
1) will have their BP measured by the office method at 
all scheduled visits (at 0, 3, 6, 12, 18, 24, 30, 36, 42 and 48 
months). In these patients, ABPM will only be performed 
at randomisation visit and at follow-up visits 3, 5, 7 and 9 
and in case of premature discontinuation (ie, patients’ deci-
sion to withdraw, non-compliance with the study protocol) 
at any time. However, ABP values will not be used by the 
investigator to take treatment decisions, but treatment will 
be based on OBP only. According to the ABPM procedures 
manual of the MASTER Study, data of these patients will not 
be made available to the investigators in charge of treatment 
decisions, but will be directly uploaded on the study website 
(table 1). As indicated in table 1, additional tests and exam-
inations will be performed at different time points during 
the study follow-up. For assessment of LV mass and function, 
both B mode and M mode two-dimensional (2D) echocar-
diographic measurements and calculation of LVM will be 
performed according to current American Society of Echo-
cardiography guidelines.15–18 LVM will be calculated with 
the formula for estimation of LVM from LV linear dimen-
sions.18 In order to account for obesity-related LV hyper-
trophy (LVH),16 17 correction of LVM will be performed 
both for height and for body surface area (BSA) using the 
Dubois and Dubois formula.15 17 Since LVM values differ 
between men and women, with the latter being systemati-
cally lower than the former, even when indexed for BSA, the 
presence of LVH will be defined on the basis of upper limits 
of normality for LVM of >115 g/m2 (>48 g/m 2.7) in men 
and >95 g/m2 (>44 g/m 2.7) in women following recommen-
dations for cardiac chamber quantification by echocardiog-
raphy in adults.18 Patterns of LVH (concentric vs eccentric) 
and remodelling will also be considered. LV systolic function 
will be estimated by calculating ejection fraction by means 
of the biplane method of disks summation (modified Simp-
son’s rule), which is the recommended 2D echocardio-
graphic method by consensus.18 Diastolic function will also 
be assessed by considering the following parameters: mitral 
inflow pulsed wave (PW) Doppler, Doppler Tissue Imaging 
(DTI) of mitral annulus, PW Doppler of pulmonary vein 
flow, tricuspidal valve velocity peak calculated by continuous 
wave (CW) Doppler and indexed left atrial volume (biplane 
maximal left atrial volume will be calculated using the area-
length method, and then indexed by BSA) as indicated by 
current guidelines.19 20
ECG recordings will also be performed at different time 
points of the study in order to identify the presence of 
ECG LVH. This will be done by means of specific indices 
such as Cornell Voltage Product and Index and Sokolow-
Lyon Index.
The coprimary end point of urinary albumin excretion 
(UAE) will be evaluated from morning spot urine samples 
and expressed as UACR (mg/g). Spot urine samples will 
be taken twice, once in the morning before application 
of the ABPM device, and another time on the following 
morning when the ABPM device will be removed.
Blood samples will also be obtained for determination 
of serum creatinine, glucose, HbA1c, uric acid, Na+, 
K+ and lipids as well as to create a study biobank.
At each follow-up visit, physicians will not only ascertain 
achievement of BP control and/or adjust antihyperten-
sive treatment if needed, but they will also record the type 
of antihypertensive therapy, presence of concomitant 
medications and adverse events on the study e-CRF for 
study safety evaluation (Table 1).
Given that the trial inclusion criteria establish that all 
patients in MASTER should have OBP controlled by treat-
ment (ie, systolic OBP <140 and diastolic OBP <90 mm Hg), 
all patients in group 1 will have their antihypertensive treat-
ment unmodified at the randomisation visit. If at any of 
the subsequent trial visits, SBP or DBP will exceed normal 
values (ie, SBP ≥140 or DBP ≥90 mm Hg), antihypertensive 
treatment will be intensified according to available guide-
lines (figure 1). Patients randomised to be managed based 
on ABPM (group 2) will have their BP measured by the 
ambulatory method at all scheduled visits. OBP will also be 
measured at all visits, but it will not be used by the investigator 
to take treatment decisions. Given that the trial inclusion 
criteria establish that all patients in MASTER should have 
uncontrolled ambulatory SBP or diastolic BP (DBP) values 
(24 hour or daytime or night-time), all patients in group 2 
will have their antihypertensive treatment intensified at the 
randomisation visit and at any of the subsequent trial visits, 
in which ambulatory SBP or DBP will exceed normal values 
(ie, 24 hour SBP ≥130 or 24 hour DBP ≥80 mm Hg; daytime 
SBP ≥135 or daytime DBP ≥85; night-time SBP ≥120 or night-
time DBP ≥70 mm Hg), according to available guidelines 
(figure 1). In case only daytime or night-time target values 
are not achieved, change in timing of doses to morning 
or evening, respectively, should be considered. At each 
follow-up visit, achievement of ABP control will be ascer-
tained and antihypertensive treatment will be adjusted if 
needed, according to guidelines (figure 1). Patients’ adher-
ence will also be encouraged and monitored.
sample size calculation
Sample size calculation was based on the primary study 
endpoint of changes in left ventricular mass index (LVMI) 
at 12th month. We do not know what proportion of the 
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enrolled patients will have a diagnosis of LVH; therefore, 
the primary endpoint has not been based on categorical 
changes in LVH but rather on changes in LVM as a contin-
uous variable. As the enrolled individuals are hypertensive 
patients with BP incompletely controlled by treatment, 
we expect LVM to be often higher than in subjects with 
sustained BP control (normal OPB and ABP levels). To 
calculate the sample size, we have assumed a difference of 
5 g/m2 in the change of LVMI with the ABP-guided (group 
2) compared with the OBP-guided (group 1) manage-
ment strategy. This has been based on the consideration 
that SBP will be reduced by about 8 mm Hg more in the 
ABP-guided group, as well as on the echocardiographic 
data of studies such as REGAAL and CATCH in which 
differences in echo LVMI changes between treatments 
producing similar BP reductions were lower than 3 g/
m2.20 21 The SD of ±25 g/m2 was also derived from data of 
REGAAL and CATCH as well as from previous assessment 
of within operator reproducibility.21 22 Considering a 
LVMI difference between groups of 5.0 g/m2 and a SD of 
25 g/m2, an alpha of 0.025 (one-sided t-test) and a power 
(1-beta) of 90%, with a dropout rate of 15% during the 
study period, a minimum of 620 subjects per study group 
was deemed necessary, for a total number of 1240 subjects 
to be randomised. However, given the uncertainty about 
the true LVMI difference we might observe and/or the 
related SD, performance of an interim analysis has been 
decided aimed at a possible re-estimation of the sample 
size. This analysis will be carried out at 18th month when 
about 30% of randomised patients will achieve 1 year of 
follow-up. A re-estimation of the sample size will be calcu-
lated using the method of conditional power.23
outcomes
Primary, secondary and tertiary outcomes are listed in 
box 2.
Patient and public involvement
Neither patients nor public have been involved during 
the design of MASTER Study. We only explored, in a 
pilot survey, how often OBP control was accompanied by 
persistence of elevated BP values at home in a number of 
patients referred to our hypertension centre. Results of 
MASTER study will be published in peer-reviewed scien-
tific journals regardless of the outcome. Besides, MASTER 
study results will be available at https:// clinicaltrials. gov/ 
either to patients or general public. Finally, assessment of 
the burden of the intervention has not been foreseen in 
the present study.
data collection and data statement
All data collected locally at each enrolling unit will be 
recorded into an electronic e-CRF on the website of the 
trial (https:// master. digitalcrf. eu). Clinical data to be 
input into the e-CRF include demographic information, 
results on blood and urine laboratory tests performed 
locally (ie, plasma creatinine and eGFR, fasting glucose, 
uric acid, Na+, K+, Lipid profile, HbA1c, urinary sedi-
ment), ongoing antihypertensive treatment (number and 
dose of antihypertensive drugs), report forms for adverse 
events during follow-up. Digital files containing raw data 
from imaging (echocardiograms) and device-based exam-
inations (ABPM, HBPM data, ECG tracings) will also be 
uploaded on the study website linked to the study e-CRF 
for further analysis by the central reading sites.
data management
Clinical data and recordings obtained with the various 
technologies will be uploaded in the study e-CRF and 
on the study website under online control by the Data 
Management Coordinating centre, which includes an 
audit trail system. The quality of data obtained with 
the different technologies (ie, echocardiograms, ECG, 
ABPM, HBPM) will be validated by expert personnel at 
Figure 1 Randomisation groups and patient flow in the study. ABPM, ambulatory blood pressure monitoring; AHT, 
antihypertensive treatment; BP, blood pressure. 
 o
n
 11 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021038 on 19 December 2018. Downloaded from 
7Parati G, et al. BMJ Open 2018;8:e021038. doi:10.1136/bmjopen-2017-021038
Open access
the central reading sites. The occurrence of CV events 
(stroke, myocardial infarction, all major CV events, 
CV death, all cause death) and renal outcomes reported 
by each centre and supported by clinical source docu-
ments (ie, diagnostic tests, medical reports) will be vali-
dated by an adjudicating committee of experts blinded 
to assigned management strategy, BP values and organ 
damage measurements.
data analysis plan
Descriptive analysis 
Continuous data will be summarised by means of mean 
value, median, minimum, maximum, SE, SD and number 
of observations. Moreover, a 95% CI for the mean value 
will be provided. Categorical data will be summarised by 
means of absolute and relative frequencies. All these anal-
yses will be performed per management group as well as 
for the study population as a whole. Unpaired t-test (or 
Mann-Whitney U test in case of non-normal distribution) 
for continuous variables or χ2 test for categorical ones in 
order to evaluate significant between-group differences at 
baseline will be applied. The incidence of adverse events 
will be tabulated by treatment group.
Statistical methods for coprimary endpoint analysis
We will consider two coprimary endpoints: change from 
baseline to 12th month in LVMI and in albumin:creati-
nine ratio. Each endpoint will be analysed by means of 
the analysis of covariance, adjusting the group effect for 
the baseline value of LVMI (or albumin:creatinine ratio) 
and for baseline covariates resulting significantly different 
between groups. Moreover, to have a valid inference, as 
suggested by several authors, we will adjust the model for 
all variables used in the dynamic allocation scheme.14 The 
assumption of parallelism will be tested by introducing 
one or more crossproduct terms between groups and 
continuous covariates to the model.
box 2 study outcomes
Coprimary outcomes
1. Changes from baseline to 12th month in echo left ventricular mass 
index (LVMI, g/m2).
2. Changes from baseline to 12th month in urine albumin:creatinine 
ratio (UACR, mg/g, morning spot sample).
secondary outcomes
1. As compared with baseline, presence or absence of echo left 
ventricular hypertrophy (LVH) (LVMI ≥115 g/m2 (men) or ≥95 g/m2 
(women)) at 12th, 24th, 36th and 48th month.
2. Changes in ECG indices of LVH (Cornell Product (main index), 
Cornell Voltage Index, Sokolow-Lyon Score) from baseline to 12th, 
24th, 36th and 48th month.
3. As compared with baseline, presence or absence of ECG LVH: 
(Sokolow-Lyon Index  ≥3.5 mV or Cornell Voltage Index  ≥2.4 mV 
(men) or ≥2.0 mV (women) or Cornell Voltage Product ≥244 mVms) 
at 12th, 24th, 36th and 48th month.
4. Increase of microalbuminuria (defined as increase in UACR by 
100%) from baseline to 12th, 24th, 36th and 48th month.
5. Decrease of microalbuminuria (defined as reduction in UACR by 
50%) from baseline to 12th, 24th, 36th and 48th month.
6. Changes in estimated glomerular filtration rate (eGFR) (mL/
min/1.73 m2), according to Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) creatinine equation (2009) from baseline 
to 12th, 24th, 36th and 48th month.
7. As compared with baseline, presence or absence of CKD 
(eGFR <60 mL/min/1.73 m2) at 12th, 24th, 36th and 48th month.
8. The first occurrence of a composite endpoint of events including 
fatal and non-fatal stroke, acute myocardial infarction, angina, 
revascularisation procedures (coronary, carotid, iliaco-femoral), 
transient ischaemic attack, atrial fibrillation, cardiovascular death, 
hospitalisation for heart failure, progression to  severe CKD 
(eGFR<30 mL/min/1.73 m2 (CKD-EPI creatinine equation (2009)), 
or doubling serum creatinine until 48th month.
9. Changes from baseline in echo LVMI at 24th, 36th and 48th month.
10. Changes from baseline in UACR at 24th, 36th and 48th month.
tertiary outcomes
1. Changes from baseline in office blood pressure (OBP) at 3rd, 6th, 
12th, 24th, 36th and 48th month.
2. Changes from baseline in ambulatory blood pressure (ABP; 
24 hours, daytime and night-time BP) at 12th, 24th, 36th and 48th 
month.
3. Changes from baseline in home blood pressure (HBP) at 12th and 
48th month.
4. Proportions of patients with controlled BP measured with OBP, HBP 
or ABP, respectively, at 12th and 48th month.
5. Proportions of patients with controlled BP measured with OBP and 
ABP at 3, 6, 12 and 48 months (only for ABP group). Proportions of 
patients with controlled BP measured with OBP and HBP at 3, 12 
and 48 months (for both groups).
6. Number of prescribed antihypertensive drugs at 3rd, 6th, 12th and 
48th month.
7. Changes over time in the diagnosis of masked uncontrolled hy-
pertension (on the basis of ABPM+OBP) at 12th and 48th month.
8. Comparison of the prevalence of masked uncontrolled hyperten-
sion (on the basis of HBPM+OBP or of ABPM+OBP, respectively) at 
12th and at the 48th month.
9. Comparison between groups in visit-by-visit BP variability (standard 
deviation (SD); Coefficient of variation (CV); variability independent 
Continued
box 2 Continued
of the mean (VIM); average real variability (ARV)).
10. Comparison between groups in 24 hour BP variability (24 hours SD; 
24 hours weighted SD  (wSD); ARV) at 12th, 24th, 36th  and 48th 
month.
11. Comparison between groups in day-by-day BP variability (SD, VC, 
ARV, maximun (MAX) BP) at 12th and 48th month.
12. Comparison between groups in Smoothness Index and treat-
ment-on-variability index (TOVI)  at 12th and 48th month.
13. Comparison between groups in the correlation between chang-
es from baseline to 12th, 24th, 36th and 48th month in LVMI and 
changes from baseline to 12th, 24th, 36th and 48th month of dif-
ferent measures of BP (OBP, ABP and HBP).
14. Comparison between groups in the correlation between changes 
from baseline to 12th, 24th, 36th and 48th month in albuminuria 
and changes from baseline to 12th, 24th, 36th and 48th month of 
different measures of BP (OBP, ABP and HBP).
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Statistical methods for secondary endpoint analysis
For all secondary endpoints, except for endpoint 8, we 
will consider a repeated measurement approach based 
on mixed models which contain both fixed effects (eg, 
BP measurement technique) and random effects (eg, 
patient). These models are likelihood-based approaches 
in the presence of ignorable missing data (ie, missing at 
random) and are a proper way to accommodate informa-
tion on a patient with postrandomisation outcomes, even 
when such a patient’s profile is incomplete.24 In partic-
ular, for endpoints 1, 3, 4, 5 and 7, a repeated-measures 
model for dichotomous endpoints will be applied, while 
for endpoints 2, 6, 9 and 10, we will consider a model 
for continuous outcome. In both cases, the main purpose 
will be to determine whether the within-person changes 
over time vary across levels of one or more between-
person factors (eg, BP measurement technique and for 
the same covariates included in the model for copri-
mary endpoints).14 For endpoint 8, cumulative propor-
tion surviving curves according Kaplan-Meier will be 
obtained for each group and compared with the method 
of log-rank test. In order to explore the group effect 
on the timetoevent of composite outcome adjusting for 
baseline covariates, the Cox regression model will be 
fitted. Though the Cox model is non-parametric to the 
extent that no assumptions are made about the form of 
the baseline hazards, two important issues of non-infor-
mative censoring and proportional hazards will need to 
be verified. To satisfy the first assumption, the design of 
the underlying study must ensure that the mechanisms 
giving rise to censoring of individual subjects are not 
related to the probability of an event occurring. Care will 
be taken that continuation of follow-up does not depend 
on a participants medical condition. To satisfy the second 
assumption, the χ2 tests of proportional hazards assump-
tion and the log-cumulative hazard plots will be made. 
If the assumption of proportionality is deemed reason-
able, the assumptions of linearity and additivity, which 
are implicit in the linear predictor formula, will be 
considered. Although the composite endpoint could be 
misleading, we will not proceed to analyse each individual 
event considering the other events as competing causes 
of failure because also competing risk analysis can be 
misleading. Randomised controlled trials are frequently 
not powered to detect an effect of the intervention on 
individual components and competing risks analysis 
might have a low chance of detecting a true effect.25
Statistical methods for tertiary endpoint analysis
For endpoints 1–3, we will apply mixed models proposed 
for secondary endpoints. For endpoints 4–12, we will 
apply the χ2 test for dichotomous endpoints, the t-test 
(or median test whenever necessary) for continuous 
endpoints and, specifically for variation coefficients, 
the large sample Z test as suggested by Bhoj et al.26 For 
endpoints 13 and 14, the differences between the Pearson 
correlation coefficients of two groups will be calculated 
and reported with their 95% CI using the approach 
proposed by Zou.27 The handling of missing data will be 
based on a multiple imputation approach.24 All statistical 
tests will be interpreted at the 5% significance level consid-
ering two-sided test, unless specified otherwise. All statis-
tical analyses will be performed by the Statistical Centre 
of Istituto Auxologico Italiano, Milan. Statistical packages 
will be used for the analyses, chosen among Stata (STATA 
data analysis and statistical software, Texas, USA), R (The 
R project for statistical computing, free software) and SAS 
(SAS Institute, Cary, North Carolina, USA).
Ethical considerations
MASTER study protocol has initially received approval 
by the ethics committee of the Istituto Auxologico 
Italiano. Thus, the ethical conduct of this study will 
be under the control of an independent Data Safety 
Monitoring Board, stemming out of the Istituto 
Auxologico Italiano Ethical Review Board. This is 
an investigator-generated study and as such will be 
performed in full independence of the study sponsor 
from any other funding body. The procedures set out 
in this protocol, pertaining to the conduct, evalua-
tion and documentation, are designed to ensure that 
the sponsor and investigator abide to Good Clinical 
Practice guidelines and follow the guiding principles 
detailed in the Declaration of Helsinki. 
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